The Department of Defense, through the Defense Health Agency, is seeking proposals for the development of a fast and wide multiplexing omics assay platform that meets the criteria for Certification of Waiver (COW) status from the Clinical Laboratory Improvement Amendments (CLIA). The objective is to create an in vitro diagnostic (IVD) platform capable of detecting at least 25 multi-omics targets from a single minimally invasive biomatrix input, with high sensitivity and specificity, and minimal risk of erroneous results. This innovative platform is intended for use in austere environments, such as Role 1/2 facilities, where space and resources are limited, and aims to enhance diagnostic capabilities for multiple diseases, including sepsis and traumatic brain injury. The solicitation is currently closed, with the application due date having been June 12, 2024. For more information, interested parties can visit the official solicitation page at https://www.dodsbirsttr.mil/topics-app/.